JAZZ PHARMACEUTICALS PLC (JAZZ) Stock Analyst Ratings
USA - NASDAQ:JAZZ - IE00B4Q5ZN47 - Common Stock
139.33 USD
+0.8 (+0.58%)
139.33 USD
0 (0%)
ChartMill assigns a Buy % Consensus number of 85% to JAZZ. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 190.69. This target is 36.86% above the current price.
JAZZ was analyzed by 25 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about JAZZ.
In the previous month the buy percentage consensus was at a similar level.
JAZZ was analyzed by 25 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-10-27 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-10-20 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-09-24 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-08-29 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-08-28 | Needham | Reiterate | Buy -> Buy |
| 2025-08-28 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-08-28 | Truist Securities | Maintains | Buy -> Buy |
| 2025-08-28 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-08-20 | Needham | Reiterate | Buy -> Buy |
| 2025-08-06 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-07-22 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-06-11 | Needham | Reiterate | Buy -> Buy |
| 2025-06-03 | Needham | Reiterate | Buy -> Buy |
| 2025-05-07 | Needham | Reiterate | Buy -> Buy |
| 2025-05-07 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-05-07 | Baird | Maintains | Outperform -> Outperform |
| 2025-05-07 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-05-07 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2025-04-10 | Needham | Reiterate | Buy -> Buy |
| 2025-03-10 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-03-07 | UBS | Upgrade | Neutral -> Buy |
| 2025-03-06 | Truist Securities | Maintains | Buy -> Buy |
| 2025-03-05 | Needham | Reiterate | Buy -> Buy |
| 2025-02-27 | Barclays | Maintains | Overweight -> Overweight |
| 2025-02-26 | Cantor Fitzgerald | Downgrade | Overweight -> Neutral |
| 2025-02-26 | Needham | Maintains | Buy -> Buy |
| 2025-02-26 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-02-26 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-02-26 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2025-02-13 | Wells Fargo | Upgrade | Equal-Weight -> Overweight |
JAZZ PHARMACEUTICALS PLC / JAZZ FAQ
What do analysts expect the price target to be for JAZZ PHARMACEUTICALS PLC (JAZZ)?
25 analysts have analysed JAZZ and the average price target is 190.69 USD. This implies a price increase of 36.86% is expected in the next year compared to the current price of 139.33.
What is the consensus rating for JAZZ stock?
The consensus rating for JAZZ PHARMACEUTICALS PLC (JAZZ) is 84.8 / 100 . This indicates that analysts generally have a positive outlook on the stock.
What is the number of analysts for JAZZ stock?
The number of analysts covering JAZZ PHARMACEUTICALS PLC (JAZZ) is 25.